SPATA41: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

Target Name: SPATA41

NCBI ID: G388182

SPATA41

Other Name(s): spermatogenesis associated 41 | Spermatogenesis associated 41, transcript variant 1 | SPATA41 variant 1 | HSD47

SPATA41: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

SPATA41, also known as spermatogensis associated 41, is a non-coding RNA molecule that has been identified in the mouse testis. It is a key regulator of spermatogonial development and has been shown to play a role in the aging process.

Recent studies have suggested that SPATA41 may have potential as a drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and immune-related disorders.

SPATA41 is a non-coding RNA molecule that is expressed in a variety of tissues throughout the body, including the brain, heart, and testes. It is composed of 198 amino acid residues and has a calculated molecular mass of 21.9 kDa. SPATA41 is predominantly expressed in the testes, where it is a key regulator of spermatogonial development.

SPATA41 is involved in the regulation of several key processes in spermatogonial development, including the control of gene expression, DNA replication, and cell division. It has been shown to play a role in the development and maintenance of spermatogonial stem cells, which are a crucial part of the male reproductive system.

SPATA41 has also been shown to be involved in the regulation of differentiation and plasticity. In addition, it has been linked to a variety of diseases, including cancer, neurodegenerative diseases, and immune-related disorders.

One of the most promising aspects of SPATA41 is its potential as a drug target. Studies have shown that SPATA41 can be targeted with small molecules and antibodies, and that it is expressed in a variety of tissues and cells throughout the body. This suggests that it may be a promising target for a variety of diseases.

In addition to its potential as a drug target, SPATA41 may also be a useful biomarker for certain diseases. Its expression has been shown to be altered in a variety of diseases, including cancer, neurodegenerative diseases, and immune-related disorders. This suggests that it may be a valuable diagnostic or predictive tool in these diseases.

Overall, SPATA41 is a fascinating molecule that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in spermatogonial development and its potential as a therapeutic agent.

Protein Name: Spermatogenesis Associated 41

The "SPATA41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets